Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ACTRN12626000231347) titled 'Single and Multiple-Ascending Dose Study of ACE-2223-1 in Healthy Adult Participants (Part A and Part B)' on Feb. 24.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Blinded (masking used)
Assignment: Parallel
Type of endpoint: Safety
Primary Sponsor: Acelot, Inc.
Condition:
Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS)
Neurological - Neurodegenerative diseases
Intervention:
This is a Phase 1 first-in-human study of orally administered ACE-2223-1 consisting of single and multiple ascending dose parts in healthy adult...